BIT
GNMX

BlackRock Institutional Trust’s Aevi Genomic Medicine Inc GNMX Stock Holding History

BlackRock Institutional Trust’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$3.36M Sell
648,053
-3,180
-0.5% -$16.7K ﹤0.01% 2869
2016
Q3 		$3.63M Buy
651,233
+26,236
+4% +$150K ﹤0.01% 2821
2016
Q2 		$3.47M Buy
624,997
+37,434
+6% +$197K ﹤0.01% 2836
2016
Q1 		$2.58M Sell
587,563
-3,000
-0.5% -$12.3K ﹤0.01% 2937
2015
Q4 		$3.56M Buy
590,563
+84,638
+17% +$575K ﹤0.01% 2878
2015
Q3 		$3.96M Buy
505,925
+82,718
+20% +$641K ﹤0.01% 2828
2015
Q2 		$2.59M Buy
423,207
+106,768
+34% +$827K ﹤0.01% 3013
2015
Q1 		$2.55M Buy
316,439
+33,900
+12% +$256K ﹤0.01% 3001
2014
Q4 		$1.43M Buy
282,539
+11,274
+4% +$55.7K ﹤0.01% 3250
2014
Q3 		$1.41M Buy
271,265
+24,818
+10% +$160K ﹤0.01% 3211
2014
Q2 		$1.92M Buy
246,447
+19,052
+8% +$135K ﹤0.01% 3209
2014
Q1 		$1.59M Buy
227,395
+50,376
+28% +$393K ﹤0.01% 3265
2013
Q4 		$1.06M Buy
177,019
+77,764
+78% +$509K ﹤0.01% 3378
2013
Q3 		$774K Buy
99,255
+2,658
+3% +$12.3K ﹤0.01% 3433
2013
Q2 		$367K Buy
+96,597
New +$396K ﹤0.01% 3548

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock Institutional Trust's GNMX Position: Q4 2016 in Review

BlackRock Institutional Trust reduced its Aevi Genomic Medicine Inc (GNMX) stake by 0.49% in Q4 2016, selling an estimated $16.7K and leaving 648,053 shares worth $3.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2869.

BlackRock Institutional Trust first reported a position in GNMX in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.96M in Q3 2015. 76 funds tracked by Wall St. Rank hold GNMX as of Q4 2016.

  • BlackRock Institutional Trust held 648,053 shares of Aevi Genomic Medicine Inc worth $3.36M as of Q4 2016.
  • BlackRock Institutional Trust sold 3,180 Aevi Genomic Medicine Inc shares in Q4 2016, an estimated $16.7K.
  • Aevi Genomic Medicine Inc made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2869 holding.
  • BlackRock Institutional Trust first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Institutional Trust's Aevi Genomic Medicine Inc position peaked at $3.96M in Q3 2015.
  • 76 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.